Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR) from its SEC filings: 2025 revenue $39.2 million (-17% vs the year before), net margin 794%, free cash flow -$234.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $39.2 million |
| Revenue growth | -17% |
| Net income | $311.4 million |
| Net margin | 794.0% |
| Free cash flow | -$234.3 million |
| Diluted EPS | $-3.69 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +466% |
| Cash | $124.5 million |
| Share count, 1 year | +16% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.